News
Find the latest news releases and offical MDS statements.
News Releases & Position Statements
Featured Research: 2024 International Congress
September 27, 2024
Viewpoint: Biological Frameworks of Parkinson's Disease
Position: Biological Definition, Staging, and Classification of Parkinson’s Disease
December 14, 2023
A Statement of the MDS on Biological Definition, Staging, and Classification of Parkinson's Disease
Position: Diagnosis of Parkinson’s Disease
March 1, 2023
Position: Unproven Cell-Based Therapies
February 9, 2021
Official Statements: COVID-19
Issued in June 2020
MDS News Archive
Featured abstracts:
- Diabetes treatment shows potential as an adjunct therapy for early Parkinson’s disease
- First Tunisian study examining age of onset for biallelic mutations in Huntington’s disease
- Machine learning algorithm applied in classifying tic from non-tic movements
- Machine learnings has potential to assist with diagnosis in Parkinsonian syndromes
- Novel application of machine learning approaches predicts gait dysfunction in Parkinson’s disease
- Safety and efficacy of gene therapy studied in minipigs with Huntington’s disease
- Three months of probiotic therapy shown to reduce motor and nonmotor Parkinson’s disease symptoms
MDS journal news:
- MDS Task Force on Pediatrics publishes recommendations for transitional care for young people with movement disorders
- New data validates an association between trauma-related disorders and the development of Parkinson’s disease in military veterans
- Reduced Quality of Life in People with Parkinson’s Disease of Minority Racial Groups
- Characteristics of Hospitalized COVID-19 Patients with Parkinson’s Disease
- Cost and Availability are Major Barriers in Genetic Testing for Parkinson’s Disease Patients
- The Promising Effects of an α-synuclein Targeted Immunotherapy in Treating Early Parkinson’s Disease
- Reduction of LRRK2 in Human Cerebrospinal Fluid with LRRK2 Small Molecule Inhibitors
- Results from Phase 2 Study of Essential Tremor Therapeutic Shows Improved Upper Limb Tremor
- Active Immunotherapeutic PD01A for Parkinson’s Disease Phase I Clinical Study
- Early Inflammation as a Potential Predictor of Severe Decline in Nigrostriatal Function
- Multicenter, Deep Brain Stimulation Study Suggests Increased Range of Effective Stimulus Amplitude Using Directional vs. Omnidirectional Leads
- The Association of Loneliness with Quality of Life and Disease Severity in Parkinson’s Disease
- Lower Serum Biomarkers Found in Early Untreated Parkinson’s Disease
- High Intensity Interval Training May Elevate Serum BDNF Levels in Parkinson’s Disease Patients
- Worldwide Online Survey Aims to Identify a New Comprehensive Approach to Global Collaboration for Parkinson’s Disease
- Patient’s Perception of Non-Motor and Motor Function Successfully Models Parkinson’s Disease Severity
- Safety and Biomarker Effects of Novel Therapeutic for Parkinson’s Disease with GBA Mutations
- Short-term study of Ecopipam Shows Reduction of Tics in Children with Tourette Syndrome
- Regardless of Type, Exercise Improve Quality of Life and Motor Function in People with Parkinson’s Disease
- Climbing Shown to Improve Posture in People with Parkinson’s Disease
- Results from the PPMI Study on an Alpha-Synuclein Seed Amplification Assay
- Use of Continuous Circadian Intracerebroventricular Administration of Anaerobic-Dopamine Reduces Levodopa-Related Complications
- Results from a Phase III Clinical Trial for Subcutaneous Infusion of Foslevodopa/Foscarbidopa
For the Media
About MDS
The International Parkinson and Movement Disorder Society (MDS), an international society of more than 11,000 clinicians, scientists, and other healthcare professionals, is dedicated to improving patient care through education and research. Read more about MDS »
MDS's Apparent Authority Policy (PDF)
Submit a logo request form to the International Secretariat (PDF)
Contact Information
Shea Higgins, Assistant Director of Communications
International Parkinson and Movement Disorder Society
555 E. Wells Street - Suite 1100
Milwaukee, WI 53202 USA
Tel: +1 414-276-2145
Fax: +1 414-276-3349
E-mail: shiggins@movementdisorders.org
All other inquiries: info@movementdisorders.org